Avalo Therapeutics, Inc. (AVTX) stock
AVTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$7.37−0.39 (-5.03%)
Close on Nov 16, 2026Market cap $395.25MP/E –Yield –
Avalo Therapeutics enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
Avalo Therapeutics's enterprise value was -$22.02M on Nov 11, 2026, against $227.13M a year earlier. Over the last 5 years it ranged from -$98.41M to $550.90M, with a median of $10.61M.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | -$22.02M | -110.4% |
| 2025 | Dec 31, 2025 | $212.15M | – |
| 2024 | Dec 31, 2024 | -$9.92M | – |
| 2023 | Dec 29, 2023 | -$2.89M | -106.1% |
| 2022 | Dec 30, 2022 | $46.97M | -60.6% |
| 2021 | Dec 31, 2021 | $119.29M | -27.3% |
| 2020 | Dec 31, 2020 | $164.20M | -33.7% |
| 2019 | Dec 31, 2019 | $247.61M | +77.0% |
| 2018 | Dec 31, 2018 | $139.86M | +135.6% |
| 2017 | Dec 29, 2017 | $59.36M | +2417.2% |
| 2016 | Dec 30, 2016 | $2.36M | -54.6% |
| 2015 | Dec 31, 2015 | $5.20M | – |
See a number that looks wrong?